Join

Compare · ALRN vs VKTX

ALRN vs VKTX

Side-by-side comparison of Aileron Therapeutics Inc. (ALRN) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ALRN and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • VKTX is the larger of the two at $3.30B, about 87.5x ALRN ($37.7M).
  • VKTX has hit the wire 8 times in the past 4 weeks while ALRN has been quiet.
  • VKTX has more recent analyst coverage (23 ratings vs 0 for ALRN).
MetricALRNVKTX
Company
Aileron Therapeutics Inc.
Viking Therapeutics Inc.
Price
$2.13+2.90%
$28.45-4.42%
Market cap
$37.7M
$3.30B
1M return
-
-11.84%
1Y return
-
+2.25%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2017
2015
News (4w)
0
8
Recent ratings
0
23
ALRN

Aileron Therapeutics Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

VKTX

Viking Therapeutics Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Latest ALRN

Latest VKTX